A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
Gabriela Gonzalez(Center of Molecular Immunology (Cuba)), A. Lage(Center of Molecular Immunology (Cuba)), Yanela Santiesteban González(Center of Molecular Immunology (Cuba)), Tania Crombet(Center of Molecular Immunology (Cuba)), Gerardo Guillén(Hunan City University), V. Mirabal, Mauricio Catalá, Juan C. Hernández, Patricia Marinello(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 155
Related Papers
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
|The Lancet Haematology|2019|247
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
|Frontiers in Endocrinology|2020|134